OMEROS CORP
OMERNasdaq
$9.69
↑ +5.1%Jul 17 close · end-of-day
Price
1Y↑ +176.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$873.2M
Enterprise Value
$737.9M
P/E
8.4
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-10.8%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
$86.2M
Free Cash Flow (TTM)
-$94.8M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-136.1%
ROIC
—
Debt / Equity
—
Net Cash
$135.3M
Return 1Y
+178.4%
Company profile
Omeros Corporation discovers, develops, and commercializes small-molecule and protein therapeutics. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA) and atypical hemolytic uremic syndrome (aHUS) The company was incorporated in 1994 and headquartered in Seattle, Washington.
- CEO
- Gregory A. Demopulos
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 210
- Headquarters
- Washington
- Website
- omeros.com
Management & directors
- Demopulos Gregory A MdChairman, CEO & President
- Borges David J.VP, Finance & CAO
Roles derived from SEC Form 4 filings.
Earnings
OMER Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$9.9M—
Diluted EPS$0.62↓ -206.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $73.8M | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$156.9M | -$173.6M | -$163.4M | -$164.5M | -$167.0M | -$122.8M |
| Net income | -$138.1M | $194.2M | $47.4M | -$117.8M | -$156.8M | -$3.4M |
| Diluted EPS | -$2.41 | $3.12 | $0.76 | -$1.88 | -$2.70 | -$0.05 |
| Operating cash flow | -$100.1M | -$109.7M | -$86.5M | $74.7M | -$148.8M | -$116.1M |
| Free cash flow | -$100.4M | -$110.0M | -$86.6M | $74.3M | -$149.0M | -$116.2M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -212.6% | — | — | — | — | — |
| Net margin | -187.0% | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | — | — | — | $9.9M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$59.2M | -$35.4M | -$33.4M | -$35.0M | -$32.4M | -$26.4M | -$29.1M | -$17.4M |
| Net income | -$56.0M | -$32.2M | -$31.4M | -$33.5M | -$25.4M | -$30.9M | $86.5M | $56.1M |
| Diluted EPS | -$0.97 | -$0.56 | -$0.54 | -$0.58 | -$0.43 | -$0.47 | $1.43 | $0.62 |
| Operating cash flow | -$46.0M | -$32.1M | -$29.0M | -$35.8M | -$21.9M | -$18.5M | -$39.8M | -$14.5M |
| Free cash flow | -$46.1M | -$32.1M | -$29.0M | -$35.9M | -$22.0M | -$18.5M | -$39.8M | -$14.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | -176.1% |
| Net margin | — | — | — | — | — | — | — | 566.7% |
Company news
Jul 8, 2026
Jul 7, 2026
Jun 26, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-22 | Cable Thomas J. | Sale | 7,500 | $11.61 | $87,039.00 | filing |
| 2026-05-22 | Cable Thomas J. | Option exercise | 7,500 | $10.84 | $81,300.00 | filing |
| 2026-02-18 | Demopulos Gregory A MD· Chairman, CEO & President | Tax withholding | 357,678 | $11.93 | $4.3M | filing |
| 2026-02-18 | Demopulos Gregory A MD· Chairman, CEO & President | Option exercise | 400,000 | $10.27 | $4.1M | filing |
| 2026-01-13 | Borges David J.· VP, Finance & CAO | Sale | 30,000 | $12.31 | $369,315.00 | filing |
| 2026-01-13 | Borges David J.· VP, Finance & CAO | Option exercise | 30,000 | $3.06 | $91,800.00 | filing |
| 2026-01-12 | Borges David J.· VP, Finance & CAO | Sale | 30,000 | $12.72 | $381,600.00 | filing |
| 2025-10-13 | Demopulos Gregory A MD· Chairman, CEO & President | Gift | 600,000 | $0.00 | $0.00 | filing |
| 2025-10-13 | Demopulos Gregory A MD· Chairman, CEO & President | Gift | 300,000 | $0.00 | $0.00 | filing |
| 2025-10-13 | Demopulos Gregory A MD· Chairman, CEO & President | Gift | 300,000 | $0.00 | $0.00 | filing |
Latest 10 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.